| # | Country | Total Patents | |
|---|---|---|---|
| #1 | Republic of Korea | 21 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Environmental technology |
| # | Technology | |
|---|---|---|
| #1 | Microorganisms | |
| #2 | Therapeutic chemical compounds | |
| #3 | Medical preparations | |
| #4 | Peptides | |
| #5 | Climate change adaptation technologies | |
| #6 | Measuring microorganism processes |
| # | Name | Total Patents |
|---|---|---|
| #1 | Steigerwald Robin | 7 |
| #2 | Dirmeier Ulrike | 5 |
| #3 | Volkmann Ariane | 5 |
| #4 | Rountree Ryan | 4 |
| #5 | Howley Paul | 3 |
| #6 | Leyrer Sonja | 3 |
| #7 | Ward Lucy A | 3 |
| #8 | Delcayre Alain | 3 |
| #9 | Mandl Stefanie | 3 |
| #10 | Callendret Benoit Christophe Stephan | 3 |
| Publication | Filing date | Title |
|---|---|---|
| KR20200044000A | Combination therapy for cancer treatment by intravenous administration of recombinant MVA and antibody | |
| KR20170003556A | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist | |
| KR20150129027A | Single high dose of mva induces a protective immune response in neonates and infants | |
| KR20110129954A | Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines |